GlassScriptPhysician profile
Kathryn Stone
NPI 1871079103
$1,633.32
in general payments reported to CMS, 2019-2025
30 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $135 · 2024: $14.94 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.41 | 2021-2025 | |
| Pfizer INC. | $142.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.43 | 2025 | Airsupra |
| Scilex Pharmaceuticals INC. | $107.93 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $104.50 | 2021-2025 | Xtampza, Belbuca |
| Grifols USA, LLC | $87.14 | 2021 | |
| Novo Nordisk INC | $82.12 | 2025 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $72.69 | 2025 | Inspire |
| Lilly USA, LLC | $52.41 | 2021 | |
| Neurocrine Biosciences, INC. | $48.86 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $47.17 | 2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceuticals, INC. | $39.01 | 2021 | |
| Aimmune Therapeutics, INC. | $36.55 | 2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.13 | 2022-2025 | Caplyta |
| Edwards Lifesciences Corporation | $32.74 | 2025 | Sapien 3 Ultra Resilia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.53 | 2025 | Krystexxa |
| Alkermes, INC. | $31.45 | 2025 | Aristada, Lybalvi |
| Bioventus LLC | $29.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.52 | 2025 | Austedo Xr |
| Eisai INC. | $25.39 | 2021 | |
| Biodelivery Sciences International, INC. | $24.18 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.98 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.80 | 2025 | |
| Axsome Therapeutics, INC. | $18.77 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.42 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.97 | 2021 | |
| Allergan, INC. | $15.06 | 2021 | |
| Insulet Corporation | $14.54 | 2025 | Omnipod |
| Tactile Systems Technology INC | $14.39 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.